|
KR102444509B1
(ko)
|
2016-05-18 |
2022-09-19 |
미라티 테라퓨틱스, 인크. |
Kras g12c 억제제
|
|
EP3558955B1
(en)
|
2016-12-22 |
2021-08-11 |
Amgen Inc. |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
EA202091186A1
(ru)
*
|
2017-11-15 |
2020-10-01 |
Мирати Терапьютикс, Инк. |
ИНГИБИТОРЫ KRas G12C
|
|
US10597405B2
(en)
|
2017-12-08 |
2020-03-24 |
Astrazeneca Ab |
Chemical compounds
|
|
CN113121530B
(zh)
*
|
2018-01-19 |
2022-08-05 |
勤浩医药(苏州)有限公司 |
作为krasg12c突变蛋白抑制剂的吡啶酮并嘧啶类衍生物
|
|
TW201942115A
(zh)
*
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
JP7720698B2
(ja)
*
|
2018-04-04 |
2025-08-08 |
アルビナス・オペレーションズ・インコーポレイテッド |
タンパク質分解の調節因子および関連する使用方法
|
|
AU2019262589B2
(en)
*
|
2018-05-04 |
2022-07-07 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
US11932633B2
(en)
|
2018-05-07 |
2024-03-19 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
|
ES2938987T3
(es)
*
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
|
CA3100390A1
(en)
*
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
|
MX2021001706A
(es)
|
2018-08-16 |
2021-04-19 |
Hoffmann La Roche |
Compuestos de anillo fusionado.
|
|
ES2961253T3
(es)
|
2018-08-31 |
2024-03-11 |
Mirati Therapeutics Inc |
Inhibidores de KRas G12C
|
|
JP2022500385A
(ja)
*
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス, インコーポレイテッド |
組み合わせ療法
|
|
EP4552631A3
(en)
*
|
2018-09-10 |
2025-07-02 |
Mirati Therapeutics, Inc. |
Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
|
|
CA3111980A1
(en)
*
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CA3112043A1
(en)
*
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
PT3849537T
(pt)
*
|
2018-09-10 |
2025-01-22 |
Mirati Therapeutics Inc |
Terapêuticas de combinação
|
|
AU2019344897B2
(en)
|
2018-09-18 |
2024-01-18 |
Nikang Therapeutics, Inc. |
Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
|
|
CN112004802B
(zh)
|
2018-09-30 |
2021-12-28 |
凯瑞康宁生物工程(武汉)有限公司 |
作为神经元组胺受体-3拮抗剂的化合物及其用途
|
|
WO2020085493A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
新規なインダゾール化合物又はその塩
|
|
US11236068B2
(en)
*
|
2018-11-09 |
2022-02-01 |
Genentech, Inc. |
Fused ring compounds
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
CA3112129A1
(en)
*
|
2018-12-05 |
2020-06-11 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
CN113382774A
(zh)
|
2019-02-12 |
2021-09-10 |
诺华股份有限公司 |
包含tno155和krasg12c抑制剂的药物组合
|
|
EP3935060B1
(en)
|
2019-03-05 |
2023-11-15 |
Astrazeneca AB |
Fused tricyclic compounds useful as anticancer agents
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
AU2020279253A1
(en)
*
|
2019-05-20 |
2021-12-16 |
1200 Pharma Llc |
KRAS G12C inhibitors and uses thereof
|
|
EP3972963A1
(en)
|
2019-05-21 |
2022-03-30 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
US12252486B2
(en)
|
2019-05-21 |
2025-03-18 |
Amgen Inc. |
Solid state forms
|
|
PH12021552922A1
(en)
|
2019-05-21 |
2022-04-04 |
Amgen Inc |
Solid state forms
|
|
WO2020238791A1
(zh)
*
|
2019-05-24 |
2020-12-03 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
JP7584451B2
(ja)
*
|
2019-05-29 |
2024-11-15 |
上▲海▼翰森生物医▲薬▼科技有限公司 |
窒素含有複素環系誘導物レギュレーター、その製造方法及び使用
|
|
CN112047939B
(zh)
*
|
2019-06-06 |
2023-05-02 |
江苏先声药业有限公司 |
一种具有抗肿瘤活性的四氢吡啶并嘧啶类化合物
|
|
CN114040914B
(zh)
*
|
2019-07-01 |
2024-10-22 |
江苏恒瑞医药股份有限公司 |
喹唑啉酮类衍生物、其制备方法及其在医药上的应用
|
|
CN112300153B
(zh)
*
|
2019-07-26 |
2023-06-13 |
博瑞生物医药(苏州)股份有限公司 |
一种杂环化合物、药物组合物和用途
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
CN112390797A
(zh)
*
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
CN112390796B
(zh)
*
|
2019-08-19 |
2023-06-27 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
CN112430234B
(zh)
*
|
2019-08-26 |
2023-04-28 |
信达生物制药(苏州)有限公司 |
一种新型kras g12c蛋白抑制剂及其制备方法和用途
|
|
KR20220071193A
(ko)
*
|
2019-08-29 |
2022-05-31 |
미라티 테라퓨틱스, 인크. |
Kras g12d 억제제
|
|
WO2021043322A1
(zh)
*
|
2019-09-06 |
2021-03-11 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
EP4031542B1
(en)
*
|
2019-09-18 |
2025-10-15 |
Merck Sharp & Dohme LLC |
Small molecule inhibitors of kras g12c mutant
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
CN112538084B
(zh)
*
|
2019-09-23 |
2023-06-20 |
信达生物制药(苏州)有限公司 |
新颖的kras g12c蛋白抑制剂及其制备方法和用途
|
|
US11890285B2
(en)
|
2019-09-24 |
2024-02-06 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2021068898A1
(zh)
*
|
2019-10-10 |
2021-04-15 |
信达生物制药(苏州)有限公司 |
新颖的kras g12c蛋白抑制剂及其制备方法和用途
|
|
CN112694475B
(zh)
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
UA129778C2
(uk)
|
2019-10-28 |
2025-07-30 |
Мерк Шарп Енд Доум Елелсі |
Низькомолекулярні інгібітори g12c-мутантного kras
|
|
CA3159561A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
AU2020379731A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN112778301A
(zh)
*
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
WO2021093758A1
(zh)
*
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
CN112824410A
(zh)
*
|
2019-11-21 |
2021-05-21 |
苏州泽璟生物制药股份有限公司 |
氮杂七元环类抑制剂及其制备方法和应用
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
WO2021106231A1
(en)
*
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
US12479834B2
(en)
|
2019-11-29 |
2025-11-25 |
Taiho Pharmaceutical Co., Ltd. |
Phenol compound or salt thereof
|
|
EP4015520B1
(en)
*
|
2019-12-02 |
2025-02-19 |
280 Bio, Inc. |
Oxygen-containing heterocyclic compound, preparation method and application thereof
|
|
CN112979664B
(zh)
*
|
2019-12-02 |
2024-03-01 |
上海璎黎药业有限公司 |
一种含氧杂环化合物、其制备方法及应用
|
|
CN115135315B
(zh)
|
2019-12-20 |
2024-11-26 |
米拉蒂治疗股份有限公司 |
Sos1抑制剂
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
CN113045565A
(zh)
*
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
CN112094269B
(zh)
*
|
2020-01-01 |
2021-12-07 |
上海凌达生物医药有限公司 |
一类饱和六元环并杂环类化合物、制备方法和用途
|
|
GB202001344D0
(en)
*
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
US20230099858A1
(en)
*
|
2020-02-20 |
2023-03-30 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as kras inhibitors
|
|
CN117510492A
(zh)
|
2020-03-12 |
2024-02-06 |
德昇济医药(无锡)有限公司 |
嘧啶并杂环类化合物及其应用
|
|
TWI811656B
(zh)
*
|
2020-04-22 |
2023-08-11 |
大陸商德昇濟醫藥(無錫)有限公司 |
嘧啶并雜環類化合物及其應用
|
|
TW202144349A
(zh)
*
|
2020-04-30 |
2021-12-01 |
大陸商上海科州藥物研發有限公司 |
作為kras抑制劑的雜環化合物的製備及其應用方法
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
CN113666923A
(zh)
*
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
CN113683616A
(zh)
*
|
2020-05-18 |
2021-11-23 |
广州百霆医药科技有限公司 |
Kras g12c突变蛋白抑制剂
|
|
KR20230019462A
(ko)
|
2020-06-02 |
2023-02-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
|
|
CN111646910A
(zh)
*
|
2020-06-15 |
2020-09-11 |
中国药科大学 |
一种盐酸达泊西汀消旋体的制备方法
|
|
TW202214253A
(zh)
|
2020-06-18 |
2022-04-16 |
美商銳新醫藥公司 |
延遲、預防及治療對ras抑制劑之後天抗性之方法
|
|
JP2023531049A
(ja)
|
2020-06-24 |
2023-07-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sos1阻害剤及びkras g12c阻害剤を含む抗がん剤併用療法
|
|
CN113912608B
(zh)
*
|
2020-07-10 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
|
|
CN113980014B
(zh)
*
|
2020-07-27 |
2023-05-12 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
MX2023002942A
(es)
|
2020-09-11 |
2023-05-22 |
Mirati Therapeutics Inc |
Formas cristalinas de un inhibidor de kras g12c.
|
|
WO2022052895A1
(zh)
|
2020-09-11 |
2022-03-17 |
南京明德新药研发有限公司 |
氮杂环丁烷取代化合物的晶型
|
|
PE20231207A1
(es)
|
2020-09-15 |
2023-08-17 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer
|
|
US20230357277A1
(en)
*
|
2020-09-22 |
2023-11-09 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
KR20230094198A
(ko)
|
2020-09-23 |
2023-06-27 |
에라스카, 아이엔씨. |
3환식 피리돈 및 피리미돈
|
|
EP4223761A4
(en)
*
|
2020-09-30 |
2025-03-12 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
QUINAZOLINE COMPOUND AND ITS APPLICATION
|
|
CN116615422A
(zh)
*
|
2020-10-14 |
2023-08-18 |
珃诺生物医药科技(杭州)有限公司 |
用于靶向蛋白降解的方法和组合物
|
|
JP7654071B2
(ja)
|
2020-10-20 |
2025-03-31 |
アムジエン・インコーポレーテツド |
複素環スピロ化合物及び使用方法
|
|
WO2022087375A1
(en)
*
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel heterocyclic compounds
|
|
WO2022087371A1
(en)
*
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel bicyclic compounds
|
|
WO2022105855A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
WO2022109485A1
(en)
*
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
KR102503336B1
(ko)
|
2020-11-23 |
2023-02-23 |
동의대학교 산학협력단 |
음성지원이 가능한 반려동물의 배변 처리 패드
|
|
CN116829151A
(zh)
*
|
2020-12-15 |
2023-09-29 |
米拉蒂治疗股份有限公司 |
氮杂喹唑啉泛KRas抑制剂
|
|
CA3198885A1
(en)
|
2020-12-15 |
2022-06-23 |
Xiaolun Wang |
Azaquinazoline pan-kras inhibitors
|
|
US11999753B2
(en)
|
2020-12-16 |
2024-06-04 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-KRas inhibitors
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
WO2022140472A1
(en)
|
2020-12-22 |
2022-06-30 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
|
US20240092803A1
(en)
*
|
2021-01-08 |
2024-03-21 |
Beigene Switzerland Gmbh |
Bridged compounds as kras g12d inhibitor and degrader and the use thereof
|
|
CN116761799A
(zh)
*
|
2021-02-01 |
2023-09-15 |
南京明德新药研发有限公司 |
嘧啶并吡喃类化合物
|
|
CN116600808B
(zh)
*
|
2021-02-09 |
2024-10-22 |
苏州阿尔脉生物科技有限公司 |
一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
|
|
WO2022171143A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
5,6,7,8-四氢吡啶[3,4-d]嘧啶化合物
|
|
WO2022192332A1
(en)
*
|
2021-03-10 |
2022-09-15 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as kras inhibitors
|
|
CN116801883A
(zh)
*
|
2021-03-18 |
2023-09-22 |
四川科伦博泰生物医药股份有限公司 |
一类杂芳环化合物、其制备方法及用途
|
|
WO2022204112A1
(en)
|
2021-03-22 |
2022-09-29 |
Incyte Corporation |
Imidazole and triazole kras inhibitors
|
|
CN115124524A
(zh)
*
|
2021-03-26 |
2022-09-30 |
浙江海正药业股份有限公司 |
三环类衍生物及其制备方法和用途
|
|
MX2023011856A
(es)
|
2021-04-08 |
2024-01-08 |
Mirati Therapeutics Inc |
Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
|
|
WO2022217042A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ikena Oncology, Inc. |
Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
|
|
JP2024514127A
(ja)
|
2021-04-09 |
2024-03-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗がん剤療法
|
|
US20240239788A1
(en)
*
|
2021-04-16 |
2024-07-18 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras g12d mutant
|
|
WO2022223020A1
(zh)
*
|
2021-04-23 |
2022-10-27 |
清华大学 |
靶向活化与失活态kras g12d的抑制剂
|
|
WO2022228543A1
(zh)
*
|
2021-04-30 |
2022-11-03 |
江苏恒瑞医药股份有限公司 |
桥环类化合物、其制备方法及其在医药上的应用
|
|
MX2023013085A
(es)
|
2021-05-05 |
2023-11-16 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
|
WO2022251193A1
(en)
|
2021-05-27 |
2022-12-01 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2022250170A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
|
WO2022261210A1
(en)
*
|
2021-06-08 |
2022-12-15 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
KR20240024928A
(ko)
|
2021-06-23 |
2024-02-26 |
노파르티스 아게 |
Kras 돌연변이 단백질의 억제제로서의 피라졸릴 유도체
|
|
WO2022271823A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Newave Pharmaceutical Inc. |
Mutant kras modulators and uses thereof
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
|
|
CN117460737A
(zh)
*
|
2021-07-05 |
2024-01-26 |
四川科伦博泰生物医药股份有限公司 |
杂芳环化合物、其制备方法及用途
|
|
US12441727B2
(en)
|
2021-07-07 |
2025-10-14 |
Incyte Corporation |
Tricyclic compounds as inhibitors of KRAS
|
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
WO2023283933A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Biotech Co., Ltd. |
Compounds useful as kras g12d inhibitors
|
|
WO2023284537A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Shanghai Zion Pharma Co. Limited |
Kras g12d inhibitors and uses thereof
|
|
KR20240041917A
(ko)
|
2021-07-27 |
2024-04-01 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
|
JP2024534187A
(ja)
|
2021-08-31 |
2024-09-18 |
インサイト・コーポレイション |
Krasの阻害剤としてのナフチリジン化合物
|
|
WO2023031781A1
(en)
|
2021-09-01 |
2023-03-09 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
EP4389751A1
(en)
*
|
2021-09-03 |
2024-06-26 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
CN117222646A
(zh)
*
|
2021-09-16 |
2023-12-12 |
苏州赞荣医药科技有限公司 |
Kras g12c抑制剂和其用途
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
CN118176193A
(zh)
|
2021-10-22 |
2024-06-11 |
江苏恒瑞医药股份有限公司 |
含氮的四环化合物、其制备方法及其在医药上的应用
|
|
WO2023081840A1
(en)
*
|
2021-11-05 |
2023-05-11 |
Frontier Medicines Corporation |
Kras g12c inhibitors
|
|
CR20240233A
(es)
|
2021-12-01 |
2024-07-17 |
Univ Vanderbilt |
Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
|
|
CN118055932A
(zh)
*
|
2021-12-02 |
2024-05-17 |
上海和誉生物医药科技有限公司 |
一种kras抑制剂及其制备和在药学上的应用
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
MX2024007780A
(es)
|
2021-12-22 |
2024-09-11 |
Univ California |
Inhibidores de unión covalente de mutantes g12s, g12d y/o g12e de k-ras gtpasa.
|
|
JP2024546642A
(ja)
|
2021-12-22 |
2024-12-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんの処置のための複素芳香族化合物
|
|
CN116410145A
(zh)
*
|
2021-12-29 |
2023-07-11 |
上海泓博智源医药股份有限公司 |
一种mrtx849中间体的制备方法
|
|
CN118434740A
(zh)
*
|
2021-12-31 |
2024-08-02 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
WO2023137223A1
(en)
*
|
2022-01-17 |
2023-07-20 |
Newave Pharmaceutical Inc. |
Pan-kras inhibitors and uses thereof
|
|
TWI841200B
(zh)
*
|
2022-01-21 |
2024-05-01 |
大陸商上海湃隆生物科技有限公司 |
雜環類化合物、藥物組成物及其應用
|
|
JP7713603B2
(ja)
|
2022-02-09 |
2025-07-25 |
クアンタ セラピューティクス, インコーポレイテッド |
Krasモジュレーターおよびその使用
|
|
US20250154170A1
(en)
|
2022-02-10 |
2025-05-15 |
Bayer Aktiengesellschaft |
Fused pyrimidines as kras inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
CN116891514A
(zh)
*
|
2022-04-06 |
2023-10-17 |
润佳(苏州)医药科技有限公司 |
一种双官能化合物及其用途
|
|
US12331026B2
(en)
|
2022-03-28 |
2025-06-17 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
|
WO2023194310A1
(en)
|
2022-04-04 |
2023-10-12 |
Sanofi |
Therapeutic combination of kras g12c inhibitor and tead inhibitor
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
CN119768408A
(zh)
*
|
2022-05-13 |
2025-04-04 |
珃诺生物医药科技(杭州)有限公司 |
Kras(g12d)抑制剂
|
|
CA3257281A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics Inc |
PYRIMIDINE-BASED MODULATORS AND THEIR USES
|
|
CN117164580A
(zh)
*
|
2022-05-27 |
2023-12-05 |
苏州泽璟生物制药股份有限公司 |
一种kras g12c抑制剂的制备方法及其中间体
|
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
CN120504682A
(zh)
|
2022-06-10 |
2025-08-19 |
锐新医药公司 |
大环ras抑制剂
|
|
EP4540254A1
(en)
*
|
2022-06-14 |
2025-04-23 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
JP2025525356A
(ja)
*
|
2022-06-15 |
2025-08-05 |
ミラティ セラピューティクス, インコーポレイテッド |
アザキナゾリン汎Kras阻害剤
|
|
GB202212641D0
(en)
|
2022-08-31 |
2022-10-12 |
Jazz Pharmaceuticals Ireland Ltd |
Novel compounds
|
|
EP4593964A2
(en)
*
|
2022-09-28 |
2025-08-06 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2024081674A1
(en)
|
2022-10-11 |
2024-04-18 |
Aadi Bioscience, Inc. |
Combination therapies for the treatment of cancer
|
|
IL320639A
(en)
|
2022-11-09 |
2025-07-01 |
Revolution Medicines Inc |
Compounds, complexes and methods for their preparation and use
|
|
AU2023375457A1
(en)
|
2022-11-11 |
2025-05-01 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
TW202444727A
(zh)
|
2023-01-26 |
2024-11-16 |
美商艾維納斯手術有限公司 |
基於cereblon之kras降解protac及其相關用途
|
|
WO2024192424A1
(en)
|
2023-03-15 |
2024-09-19 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
KR20250164828A
(ko)
|
2023-03-30 |
2025-11-25 |
레볼루션 메디슨즈, 인크. |
Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
|
|
AU2024253668A1
(en)
|
2023-04-07 |
2025-11-13 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
US20240352038A1
(en)
|
2023-04-14 |
2024-10-24 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ras相關疾病或病症之組合療法
|
|
KR20240168510A
(ko)
*
|
2023-05-22 |
2024-12-02 |
주식회사 이노파마스크린 |
Kras g12d 및 g12v 돌연변이 표적 화합물 및 그 용도
|
|
CN116640104B
(zh)
*
|
2023-05-24 |
2024-04-02 |
杭州科耀医药科技有限公司 |
一种替洛利生的工业合成方法
|
|
WO2024246114A1
(en)
|
2023-05-31 |
2024-12-05 |
Boehringer Ingelheim International Gmbh |
Survivin as a biomarker for predicting the responsiveness of cancer treatment
|
|
CN116675690A
(zh)
*
|
2023-06-02 |
2023-09-01 |
北京康立生医药技术开发有限公司 |
一种肺癌治疗药物的制备方法
|
|
WO2025016899A1
(en)
|
2023-07-19 |
2025-01-23 |
Bayer Aktiengesellschaft |
Spirocyclic compounds for the treatment of cancer
|
|
WO2025026903A1
(en)
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
WO2025072462A1
(en)
|
2023-09-27 |
2025-04-03 |
Nikang Therapeutics, Inc. |
Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
WO2025067459A2
(en)
|
2023-09-29 |
2025-04-03 |
D3 Bio (Wuxi) Co., Ltd. |
Therapies for the treatment of cancer
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202535891A
(zh)
|
2023-10-20 |
2025-09-16 |
美商默沙東有限責任公司 |
Kras蛋白之小分子抑制劑
|
|
TW202527955A
(zh)
|
2023-11-27 |
2025-07-16 |
美商尼坎醫療公司 |
用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶2和週期蛋白依賴性激酶4的含有2,5-取代的嘧啶衍生物的雙功能化合物
|
|
WO2025117981A1
(en)
|
2023-12-02 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
WO2025132549A1
(en)
|
2023-12-20 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Cancer combination therapy using zongertinib and a kras g12c inhibitor
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025212828A1
(en)
|
2024-04-03 |
2025-10-09 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240536A1
(en)
|
2024-05-15 |
2025-11-20 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|